

REMARKS

The claims have been revised in conformance with U.S. practice.

Claims 14-16 are cancelled without prejudice or disclaimer thereto.

New claims 17-30 have been added.

Upon initial examination, the claims will be 1-13 and 17-30.

On pages 3, 5, 9 and 11 of the specification, “-C(CO₂H)CH₂CH₂-C(O)-” has been amended to recite “-CH(CO₂H)CH₂CH₂-C(O)-” and “-C(CO₂H)CH₂-C(O)-” has been amended to recite “-CH(CO₂H)CH₂-C(O)-”. These amendments are corrections of obvious errors as it is clear to a skilled artisan that carbon has four valences and that the fourth valence in this case is hydrogen. Further, support for these corrections can be found on page 5, lines 9-12 of the specification as filed in combination with the structural formula of DOTAGA given on page 20 of the specification. DOTAGA and DOTASA are known to a skilled artisan and are disclosed in formula (d) of Fichna et al. (“Synthesis of Target-Specific Radiolabeled Peptides for Diagnostic Imaging”, Bioconjugate Chem., Vol. 14, No. 1, page 7, 2003; submitted in the IDS of January 13, 2006).

Support for amended claims 1-13 and new claims 17-30 can be found in the specification and claims as filed. Please note that the species of claim 17 are a subgenus of the genus disclosed in claim 1 as filed.

No new matter has been added.

Favorable action on the merits is solicited.

Respectfully submitted,

Adrian MERLO et al.

By Warren Cheek Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/WRS/mjw
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 23, 2007